Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB: BOPH), a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announced the availability of the transcript for its fiscal first quarter ended September 30, 2010 earnings conference call, held on November 15th.

During the conference call, Gene Hsiao, Bohai's Chief Financial Officer, stated:

?As we move into the second and third quarters of Bohai's 2011 fiscal year, we expect to increase marketing and advertising for our growing portfolio of TCM medicines. Although we will be monitoring the growth potential of the five new products we introduced in April and May of this year, we will continue to place a particular focus on our key revenue generating products: Lung Nourishing Cream, Tongbi Capsules and Tongbi Tablets. Not only are these products reimbursable through insurance in China, two of them are sheltered from competition in some way. Tongbi Capsules are a ?protected' medicine in China, meaning Bohai is the only manufacturer permitted to sell the product, and Lung Nourishing Cream was recently awarded a patent in June lasting 20 years.?

Throughout the conference call Bohai's management team provided additional color on the Company's growing portfolio of TCM products, its enhanced awareness initiatives for US investors and, most notably, full details surrounding its record revenue and earnings numbers for the fiscal first quarter ended September 30, 2010, which include:

  • Net Revenues of $17.0 million, an increase of 22% from $14.0 million in 2009
  • Gross profit of $13.6 million, compared to $11.7 million in 2009
  • Net income of $3.0 million, an increase of 57% from $1.9 million in 2009
  • Fully diluted EPS of $0.15 for fiscal Q1 2011
  • Basic EPS of $0.18 for fiscal Q1 2011, exceeding performance for Q1 2009

Interested parties are encouraged to read a transcript of the conference call, available here:

http://www.trilogy-capital.com/autoir/boph_autoir.html

About Bohai Pharmaceuticals Group, Inc.

Based in the city of Yantai, Shandong Province, China, Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB: BOPH) is engaged in the production, manufacturing and distribution of herbal pharmaceuticals based on Traditional Chinese Medicine in China. Bohai's medicines address common health problems such as rheumatoid arthritis, viral infections, gynecological diseases, cardio vascular issues and respiratory diseases. Bohai's products are sold either by prescription through hospitals or over-the-counter through local pharmacies and retail drug store chains. Bohai has approximately 600 employees, including approximately 300 sales representatives, operating from 20 offices throughout China. Bohai's lead products, Tongbi Capsules and Tablets and Lung Nourishing Cream, are eligible for reimbursement under China's National Medical Insurance Program.

For comprehensive investor relations material, including fact sheets, research reports, presentations and video, please follow the appropriate link: Investor Relations Portal, Investor Fact Sheet and Overview Video.

For additional information, please visit Bohai's corporate website: www.bohaipharma.com.

Additional Information Relating to Bohai's Trading Data

Due to certain recent disruptions in the marketplace relating to quotations on the OTC Bulletin Board operated by FINRA (OTCBB), incomplete trading data may exist for certain companies like Bohai. Real-time trading data for Bohai on the OTCQB market is available through the below link. Readers are advised that OTCQB market is operated by the owner of otcmarkets.com, and Bohai Pharmaceuticals Group, Inc. makes no representation or warranty regarding the OTCQB market.

For real-time trading data for Bohai on the OTCQB market, including Level 2 quotes, please visit: www.otcmarkets.com/stock/boph/quote.

Cautionary Note Regarding Forward Looking Statements

This press release, the transcript referred to herein and the statements of representatives of Bohai Pharmaceuticals Group, Inc. (the ?Company?) related thereto contain, or may contain, among other things, ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are ?forward-looking statements,? including any other statements of non-historical information. These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as ?guidance,? ?projects,? ?may,? ?could,? ?would,? ?should,? ?believes,? ?expects,? ?anticipates,? ?estimates,? ?intends,? ?plans,? ?ultimately? or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the Securities and Exchange Commission (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.

Company Contact:
Bohai Pharmaceuticals Group, Inc.
Gene Hsiao, Chief Financial Officer
212-521-4470
or
Financial Communications Contact:
Trilogy Capital Partners - Asia
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com